218 related articles for article (PubMed ID: 23335805)
1. Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.
Schvoerer E; Moenne-Loccoz R; Murray JM; Velay A; Turek M; Fofana I; Fafi-Kremer S; Erba AC; Habersetzer F; Doffoël M; Gut JP; Donlin MJ; Tavis JE; Zeisel MB; Stoll-Keller F; Baumert TF
J Infect Dis; 2013 Apr; 207(8):1306-15. PubMed ID: 23335805
[TBL] [Abstract][Full Text] [Related]
2. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
[TBL] [Abstract][Full Text] [Related]
3. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH
Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644
[TBL] [Abstract][Full Text] [Related]
4. Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.
Anjum S; Wahid A; Afzal MS; Albecka A; Alsaleh K; Ahmad T; Baumert TF; Wychowski C; Qadri I; Penin F; Dubuisson J
J Infect Dis; 2013 Dec; 208(11):1888-97. PubMed ID: 23908491
[TBL] [Abstract][Full Text] [Related]
5. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.
Keck ZY; Xia J; Wang Y; Wang W; Krey T; Prentoe J; Carlsen T; Li AY; Patel AH; Lemon SM; Bukh J; Rey FA; Foung SK
PLoS Pathog; 2012; 8(4):e1002653. PubMed ID: 22511875
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
7. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
[TBL] [Abstract][Full Text] [Related]
8. A point mutation at Asn-534 that disrupts a conserved N-glycosylation motif of the E2 glycoprotein of hepatitis C virus markedly enhances the sensitivity to antibody neutralization.
Sasayama M; Shoji I; Adianti M; Jiang DP; Deng L; Saito T; Watanabe H; Kawata S; Aoki C; Hotta H
J Med Virol; 2012 Feb; 84(2):229-34. PubMed ID: 22170542
[TBL] [Abstract][Full Text] [Related]
9. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
Rafique S; Idrees M; Ali A; Iqbal M
Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
[TBL] [Abstract][Full Text] [Related]
10. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
[TBL] [Abstract][Full Text] [Related]
11. Virus-neutralizing antibodies to hepatitis C virus.
Wahid A; Dubuisson J
J Viral Hepat; 2013 Jun; 20(6):369-76. PubMed ID: 23647953
[TBL] [Abstract][Full Text] [Related]
12. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.
Bartosch B; Verney G; Dreux M; Donot P; Morice Y; Penin F; Pawlotsky JM; Lavillette D; Cosset FL
J Virol; 2005 Jul; 79(13):8217-29. PubMed ID: 15956567
[TBL] [Abstract][Full Text] [Related]
13. [Generation of six genotypes of infectious HCV pseudo-particles and detection of neutralizing antibodies in HCV patients].
Yang XF; Pan L; Wang Y; Ma L; Zhang Y; Zhou Y; Hao CQ; Ma ZY; Jia ZS
Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):903-6. PubMed ID: 24636291
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles.
Doerrbecker J; Friesland M; Riebesehl N; Ginkel C; Behrendt P; Brown RJ; Ciesek S; Wedemeyer H; Sarrazin C; Kaderali L; Pietschmann T; Steinmann E
Hepatology; 2014 Aug; 60(2):508-20. PubMed ID: 24771613
[TBL] [Abstract][Full Text] [Related]
15. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles.
Tao W; Xu C; Ding Q; Li R; Xiang Y; Chung J; Zhong J
Virology; 2009 Dec; 395(1):67-76. PubMed ID: 19793603
[TBL] [Abstract][Full Text] [Related]
16. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.
Lavillette D; Morice Y; Germanidis G; Donot P; Soulier A; Pagkalos E; Sakellariou G; Intrator L; Bartosch B; Pawlotsky JM; Cosset FL
J Virol; 2005 May; 79(10):6023-34. PubMed ID: 15857988
[TBL] [Abstract][Full Text] [Related]
17. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
19. Establishment of human clones producing neutralizing human monoclonal antibodies to the envelope E1/E2 protein of hepatitis C virus by EBV immortalization of immune CD22⁺ B cells.
Tabll A; El Abd Y; El Din NG; El Shenawy R; Abdelhafez TH; El Awady M; El-Mohamady H; Viazov S
Hum Antibodies; 2013; 22(3-4):55-65. PubMed ID: 24961863
[TBL] [Abstract][Full Text] [Related]
20. Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2).
Hadlock KG; Gish R; Rowe J; Rajyaguru SS; Newsom M; Warford A; Foung SK
J Med Virol; 2001 Sep; 65(1):23-9. PubMed ID: 11505439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
